Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

10x Genomics, Inc. - Common Stock (NQ:TXG)

10.41 +0.00 (+0.05%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about 10x Genomics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
1 Cash-Producing Stock with Exciting Potential and 2 to Ignore
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak... 
Via StockStory
1 of Wall Street’s Favorite Stock with Promising Prospects and 2 to Be Wary Of
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because... 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
TXG Q1 Earnings Call: Academic Funding Uncertainty Drives Guidance Withdrawal and Cost Reductions
Biotech company 10x Genomics (NASDAQ:TXG) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 9.8% year on year to $154.9 million. On the other hand, next quarter’s... 
Via StockStory
Topics Intellectual Property
Exposures Intellectual Property
What's Driving the Market Sentiment Around 10x Genomics?
Via Benzinga
Forecasting The Future: 7 Analyst Projections For 10x Genomics
Via Benzinga
Earnings Scheduled For May 8, 2025
Via Benzinga
Cathie Wood's Ark Invest Continues To Offload Tesla As Elon Musk Moves On From Trump Administration
Ark Invest made significant trades in TSLA, TXG, NTLA, DDD, and ADPT. Purchase of TXG and NTLA from ARKG and ARKK funds, and sale of TSLA, DDD, and ADPT from various funds. 
Via Benzinga
Topics Government
Exposures Political
Powell, Mayville Engineering, Graham Corporation, Hyster-Yale Materials Handling, and 10x Genomics Shares Skyrocket, What You Need To Know
A number of stocks jumped in the morning session after the major indices rebounded (Nasdaq +2.0%, S&P 500 +1.5%) as President Trump postponed the planned 50% tariff on European Union imports, shifting... 
Via StockStory
Topics Government Stocks World Trade
Exposures Political Tariff US Equities
Cathie Wood Reiterates 'Profound' AI Application In Healthcare As Researchers Discover 'Cancer Survival Outcomes' By Facial Photograph Analysis: Here Are The Stocks That Could Benefit
Cathie Wood underscored the application of AI in the healthcare sector by sharing new research by Mass General Brigham. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Why 10x Genomics Stock Was Sliding This Week
Via The Motley Fool
Topics Intellectual Property
Exposures Intellectual Property
1 Small-Cap Stock with Exciting Potential and 2 to Turn Down
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small... 
Via StockStory
3 Volatile Stocks Walking a Fine Line
A highly volatile stock can deliver big gains - or just as easily wipe out a portfolio if things go south. While some investors embrace risk, mistakes can be costly for those who aren’t prepared. 
Via StockStory
Analyst Expectations For 10x Genomics's Future
Via Benzinga
Cathie Wood Says AI Innovation In Healthcare Will Be More 'Profound' Than Autonomous Taxi Networks, Humanoid Robots
Cathie Wood highlights the rising applications of AI and how it is poised to impact the health care space. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
3 Stocks Under $10 Walking a Fine Line
Stocks trading in the $1-10 range are generally smaller players with less risk than their penny stock counterparts. But that doesn’t mean the underlying businesses are cheap, and we advise caution as... 
Via StockStory
10x Genomics CEO Calls NIH The 'Foundational Jewel' Of Biomedical Progress, Says 40% To 50% Of Revenue Supported By Academic And Government Research Funding — Pulls Full Year Revenue Guidance
10x Genomics Inc. criticized U.S. government budget cuts for academic research, withdrew full-year guidance, and shifted to quarterly forecasts. 
Via Benzinga
10x Genomics’s (NASDAQ:TXG) Q1: Strong Sales But Quarterly Revenue Guidance Significantly Misses Expectations
Biotech company 10x Genomics (NASDAQ:TXG) reported Q1 CY2025 results topping the market’s revenue expectations, with sales up 9.8% year on year to $154.9 million. On the other hand, next quarter’s... 
Via StockStory
10x Genomics (TXG) Reports Q1: Everything You Need To Know Ahead Of Earnings
Biotech company 10x Genomics (NASDAQ:TXG) will be announcing earnings results tomorrow after the bell. Here’s what investors should know. 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Cathie Wood Pours $9.8 Million In Robinhood Despite Crypto Revenue Slump, Keeps Dumping Palantir Ahead Of Earnings
Cathie Wood's Ark Invest Makes Bold $9.8M Robinhood Bet While Dumping Palantir Ahead of Earnings. 
Via Benzinga
Cathie Wood Sells Palantir Shares Worth $2.65 Million Ahead Of Earnings, Doubles Down On This Chip Giant
On Wednesday, April 30, 2025, Cathie Wood sold $2.65 million worth of Palantir shares through various ARK ETFs. 
Via Benzinga
3 Cash-Heavy Stocks in the Doghouse
A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face challenges like stagnating revenue, declining... 
Via StockStory
Cathie Wood Buys More NVIDIA And AMD Stock As Chinese Tech Giants Stockpile Chips Amid Looming US Export Curbs
On Wednesday, April 23, 2025, Cathie Wood of Ark Invest purchased more stock of AMD and Nvidia amid looming US chip curbs against China. 
Via Benzinga
PacBio (PACB) and Hims & Hers Health (HIMS), 10x Genomics (TXG), Moderna (MRNA) Shares Are Soaring, What You Need To Know
A number of stocks jumped in the afternoon session after markets rallied sharply on news that President Trump announced a 90-day tariff pause. Reciprocal tariffs were also dropped to 10% for most... 
Via StockStory
Topics Artificial Intelligence Government World Trade
Exposures Artificial Intelligence Political Tariff
Q4 Earnings Outperformers: 10x Genomics (NASDAQ:TXG) And The Rest Of The Life Sciences Tools & Services Stocks
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the life sciences tools & services industry, including 10x Genomics (NASDAQ:TXG) and its peers. 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
2 Reasons to Sell TXG and 1 Stock to Buy Instead
What a brutal six months it’s been for 10x Genomics. The stock has dropped 52.1% and now trades at $10.59, rattling many shareholders. This was partly due to its softer quarterly results and might have... 
Via StockStory
1 Stock Under $50 on Our Watchlist and 2 to Ignore
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some... 
Via StockStory
Life Science Company 10x Genomics Struggles With Profitability, Analyst Says 2025 Guidance Bakes In NIH Funding Uncertainties
10x Genomics reported a Q4 EPS loss of $(0.40), missing estimates, while revenue declined 10% year over year. Analysts lowered price targets amid profitability concerns. 
Via Benzinga
Why 10x Genomics (TXG) Shares Are Falling Today
Shares of biotech company 10x Genomics (NASDAQ:TXG) fell 8.5% in the pre-market session after the company reported disappointing fourth-quarter results: its EPS missed significantly, and its full-year... 
Via StockStory
MGM Resorts To Rally Around 75%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
10x Genomics (NASDAQ:TXG) Exceeds Q4 Expectations But Full-Year Sales Guidance Misses Expectations
Biotech company 10x Genomics (NASDAQ:TXG) reported Q4 CY2024 results beating Wall Street’s revenue expectations, but sales fell by 10.3% year on year to $165 million. On the other hand, the company’s... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback